KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Change in Cash: 2010-2025

Historic Change in Cash for Nektar Therapeutics (NKTR) over the last 16 years, with Sep 2025 value amounting to -$2.0 million.

  • Nektar Therapeutics' Change in Cash fell 190.18% to -$2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.9 million, marking a year-over-year increase of 131.38%. This contributed to the annual value of $9.0 million for FY2024, which is 116.95% up from last year.
  • According to the latest figures from Q3 2025, Nektar Therapeutics' Change in Cash is -$2.0 million, which was down 147.78% from $4.1 million recorded in Q2 2025.
  • Nektar Therapeutics' Change in Cash's 5-year high stood at $42.8 million during Q1 2022, with a 5-year trough of -$98.3 million in Q3 2021.
  • In the last 3 years, Nektar Therapeutics' Change in Cash had a median value of -$2.0 million in 2025 and averaged -$4.3 million.
  • Its Change in Cash has fluctuated over the past 5 years, first plummeted by 4,061.15% in 2021, then spiked by 337.96% in 2022.
  • Nektar Therapeutics' Change in Cash (Quarterly) stood at -$28.8 million in 2021, then skyrocketed by 39.13% to -$17.5 million in 2022, then slumped by 69.09% to -$29.6 million in 2023, then spiked by 147.71% to $14.1 million in 2024, then tumbled by 190.18% to -$2.0 million in 2025.
  • Its Change in Cash stands at -$2.0 million for Q3 2025, versus $4.1 million for Q2 2025 and -$5.4 million for Q1 2025.